Guangzhou Baiyunshan Pharmaceutical Holdings (00874) subsidiary has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration.

Guangzhou Baiyunshan Pharmaceutical Holdings (00874) announced that its subsidiary, Guangzhou Baiyunshan Pharmaceutical Holdings Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Guangzhou Baiyunshan Pharmaceutical Holdings Pharmaceutical Factory"), recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. BYS30 granules is a class 1 innovative traditional Chinese medicine compound formulation developed by Guangzhou Baiyunshan Pharmaceutical Holdings Pharmaceutical Factory, indicated for knee osteoarthritis.